SCHEMBL4775007

SCHEMBL4775007

OC[C@@H]1C[C@@H](c2ccccc2)CC[C@H]1Nc1cc(-c2cccnc2)nc(-c2ccccn2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP2A6 P11509 1/20 0.38
CYP2C9 P11712 2/20 0.37
CYP3A4 P08684 2/20 0.37
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
PKM P14618 1/20 0.36
TSHR P16473 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
VCP P55072 2/20 0.36
GLA P06280 1/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
BRAF P15056 1/20 0.36
IRAK4 Q9NWZ3 2/20 0.35
HIF1A Q16665 2/20 0.35
EPHX2 P34913 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4772988 0.77 CYP2A6 (0.45) CYP2A6NPC1TP53PKMTSHR
SCHEMBL4878463 0.75 SYK (0.47) CYP2A6NPC1TP53PKMTSHR
SCHEMBL4773261 0.75 SYK (0.47) CYP2A6NPC1TP53PKMTSHR
SCHEMBL4775378 0.74 MERTK (0.52) CYP2A6NPC1TP53PKMTSHR
SCHEMBL4773025 0.72 CYP2A6 (0.47) CYP2A6NPC1TP53PKMTSHR
SCHEMBL4775400 0.72 GBA1 (0.53) ALDH1A1CYP2A6CYP3A4NPC1TP53
SCHEMBL2238265 0.70 CYP3A4 (0.45) ALDH1A1L3MBTL1CYP2A6CYP2C9CYP3A4
SCHEMBL2239929 0.69 CYP3A4 (0.65) ALDH1A1L3MBTL1CYP2A6CYP2C9CYP3A4
SCHEMBL4773536 0.68 CYP2A6 (0.44) ALDH1A1CYP2A6CYP2C9CYP3A4NPC1
SCHEMBL4773513 0.68 CYP2A6 (0.44) ALDH1A1CYP2A6CYP2C9CYP3A4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed